Cancer Vaccine Developer Vaxil Receives $3M Investment

Israeli company Vaxil Biotherapeutics, which is developing vaccines for cancer and tuberculosis, has received a $3 million investment. The investment was made by Yorkville Advisors, which will transfer the funds over the next five years.

Vaxil was founded in late 2006 and is headquartered at the Weizmann Science Park.